Protein Biomarker Levels in Tissue Samples From Young Patients With Low-risk Hodgkin Lymphoma

Study Overview
=================
Brief Summary
-----------------
RATIONALE: Studying samples of tissue from patients with cancer in the laboratory may help doctors identify and learn more about changes that occur in DNA and identify biomarkers related to cancer. It may also help doctors predict how patients will respond to treatment. PURPOSE: This research trial is studying protein biomarker levels in tissue samples from young patients with low-risk Hodgkin lymphoma.

Detailed Description
-----------------
OBJECTIVES: To investigate the variability of expression of human geminal-center-associated lymphoma (HGAL) protein in pediatric low-risk Hodgkin lymphoma. To assess the variability of HGAL staining between risk groups by comparing samples from subjects enrolled in the low-risk study AHOD0431 with subject samples enrolled in AHOD0031 for intermediate-risk classical Hodgkin Lymphoma (cHL). To assess the variability of HGAL staining by evaluating a tissue array created from subjects with intermediate-risk cHL. To correlate rapid or slow early-response in the intermediate-risk group with HGAL protein expression. OUTLINE: Paraffin-embedded tissue samples and tissue microarrays are analyzed for protein expression by IHC.

Official Title
-----------------
Investigation to Evaluate the Levels of Human Germinal-center-Associated Lymphoma (HGAL) Protein in Pediatric Hodgkin Lymphoma and Correlate With Early Response

Conditions
-----------------
Lymphoma

Intervention / Treatment
-----------------
* Genetic: microarray analysis
* Genetic: protein expression analysis
* Other: immunohistochemistry staining method
* Other: laboratory biomarker analysis


Participation Criteria
=================
Eligibility Criteria
-----------------
DISEASE CHARACTERISTICS: Diagnosed with low-risk classical Hodgkin lymphoma (cHL) Samples available from patients enrolled in the low-risk study COG-AHOD0431 and in the intermediate-risk cHL study COG-AHOD0031 PATIENT CHARACTERISTICS: Not specified PRIOR CONCURRENT THERAPY: Not specified

Ages Eligible for Study
-----------------
Maximum Age: 21 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Genetic: microarray analysis|nan|
|Genetic: protein expression analysis|nan|
|Other: immunohistochemistry staining method|nan|
|Other: laboratory biomarker analysis|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Variability of HGAL protein expression in pediatric patients with low-risk classical Hodgkin lymphoma (cHL) |  |  | 
| Variability of HGAL staining between low-risk and intermediate-risk pediatric patients with cHL |  |  | 
| Variability of HGAL staining as assessed by tissue array in pediatric patients with intermediate-risk cHL |  |  | 
| Correlation of rapid or slow early response in the intermediate-risk group with HGAL protein expression |  |  | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
childhood favorable prognosis Hodgkin lymphoma, stage I childhood Hodgkin lymphoma, stage II childhood Hodgkin lymphoma, stage III childhood Hodgkin lymphoma, stage IV childhood Hodgkin lymphoma, childhood lymphocyte depletion Hodgkin lymphoma, childhood lymphocyte predominant Hodgkin lymphoma, childhood mixed cellularity Hodgkin lymphoma, childhood nodular lymphocyte predominant Hodgkin lymphoma, childhood nodular sclerosis Hodgkin lymphoma